Dr. Dave Jenkins

00:00 – Introduction

• Dr. Barrett introduces Dr. Dave Jenkins, a New Zealand-trained GP turned functional medicine physician, specializing in Alzheimer’s reversal and cognitive optimization
• Dr. Jenkins runs a wellness retreat in Bali tailored to patients with cognitive impairment, working in collaboration with Dr. Dale Bredesen

01:18 – Dr. Jenkins’ Background

• Born and trained in New Zealand; started as a family physician
• Frustrated with symptom-based medicine, transitioned to functional medicine via the American Academy of Anti-Aging Medicine
• While surfing in Indonesia, discovered extreme child mortality in remote villages; founded humanitarian charity Surf Aid, which has helped ~200,000 people over 25 years
• When siblings reported their mother developing Alzheimer’s, Jenkins contacted Dr. Dale Bredesen and became one of the first practitioners trained by Bredesen (~15 years ago)

04:00 – Alzheimer’s Reversal: The Bredesen Protocol

• Co-published with Bredesen: 100 documented cases of Alzheimer’s reversal (searchable: “100 patients Alzheimer’s reversal”)
• Bredesen’s approach: multimodal precision medicine targeting underlying drivers — metal toxicity, insulin resistance, high homocysteine, inflammation (“holes in the roof”)
• New placebo-controlled trial just published (weeks old at time of recording); Bredesen protocol shown to be 6x more effective than lecanemab (the amyloid antibody drug)
• Lecanemab carries serious side effects: brain bleeding, brain edema, death — at enormous cost
• Despite compelling evidence, mainstream neurology remains resistant due to entrenched paradigms and pharmaceutical industry influence

06:59 – Paradigm Resistance in Medicine

• Dr. Barrett recounts colleagues dismissing the concept of “Alzheimer’s reversal” in 2015 — now far less controversial
• Billions spent on drugs that do nothing or worsen outcomes
• Discussion of medicine’s slow adoption curve: 15–20 years from solid evidence to clinical practice

09:56 – pTau 217: The Game-Changing Biomarker

• pTau 217 is a fragment of the tau tangle — measurable in blood via a simple test (~$600–$1,000)
• Can detect Alzheimer’s disease process 20 years before symptoms appear
• Functions as a therapeutic monitoring tool — tracks response to interventions including gene therapy, peptides, and hyperbaric oxygen
• Dr. Jenkins plans to use it as a key metric in the upcoming “Bredesen Plus” protocols
• Connection to APOE genetics: APOE ε4 (one copy) = ~25% Alzheimer’s risk; two copies ≈ 90% risk — early testing critical for those with family history

13:32 – Know Your Risk: The Case for Testing

• Many patients say, “I don’t want to know” — but Bredesen’s reversal data changes the entire calculus
• “The train left the station 20 years before your symptoms” — early detection = early intervention
• Dr. Jenkins recounts a neighbor with mild cognitive impairment who refused to engage — “there is no disease where you will be more burdensome” to family

19:04 – Motivating the Unmotivated

• Discussion of the psychological challenge of getting intelligent, affluent patients to change behavior
• Framing health decisions through a financial/investment lens: “I would never make investment decisions like I’m making with my health”
• Arterial plaque parallels: 50% of people first learn they have heart disease when they have a fatal MI
• Pomegranate juice, oxidized LDL, ultrasound plaque measurement discussed briefly

21:20 – Clotho Gene Therapy: The Longevity Molecule

• Clotho is a natural protein/signaling molecule found in all mammals; discovered by Japanese scientist
• People with higher Clotho levels:
  • Live longer
  • Have larger brains
  • Demonstrate an 8-point IQ advantage
  • Show ~50% reduction in inflammatory markers
  • Have reduced risk of cancer, kidney disease, and diabetes
• Clotho declines with age — like hormones
• 4,000+ published studies on Clotho
• Animal studies: mice lived 30% longer; aged primates showed major cognitive improvements

24:00 – How Clotho Gene Therapy Works

• Preferred delivery method: plasmid gene therapy via electroporation — pure plasmid injected into deltoid, driven into cell nucleus via mild electrical current
• Does NOT alter DNA; sets up a “small factory” producing Clotho continuously
• Because it’s a natural molecule, the body utilizes it normally
• One human study in 5 demented patients (intranasal delivery) — dramatic cognitive improvements in all subjects
• Brazilian trial: 300+ patients, zero major adverse events reported
• Dr. Jenkins’ personal results: CNS Vital Signs composite memory score went from 66 → 97 in two months
• Clotho levels measured in blood: baseline ~300; therapeutic target ~1,000 (equivalent to a 20-year-old)

28:00 – Monitoring & Dosing

• pTau 217 used alongside Clotho level testing to track progress
• Boosters planned based on Clotho blood level thresholds
• Lifestyle factors also raise Clotho naturally: exercise is one of the most potent stimulants
• AAV viral vector delivery exists but requires immunosuppression (steroids); only available in Mexico at ~$140,000
• Plasmid version: ~$20,000 depending on package; FDA trials beginning for Alzheimer’s, Parkinson’s, and ALS

31:27 – Exercise, Depression & Psilocybin

• Exercise outperforms antidepressants; may work partly through Clotho elevation
• Heat therapy (sauna) effective for depression
• Recent 3-year follow-up on a single psilocybin therapeutic session: majority of patients still depression-free
• Ibogaine discussed: passed as “Ibogaine Act” in Texas for PTSD with strong long-lasting efficacy

33:30 – The Bali Wellness Retreat: “Bredesen Plus”

• Full-immersion functional medicine retreat in Bali designed for cognitively impaired patients
• Addresses patients who struggle with compliance or have moderate Alzheimer’s
• On-site capabilities:
  • VO₂ max and visceral fat testing
  • Red light therapy, PEMF, hyperbaric oxygen (hyperoxia/hypoxia protocol)
  • IV cerebral peptides (Cerebrolysin — approved in 70 countries, unavailable in the US)
  • Stem cells, IV choline, peptide nasal sprays
  • Ketogenic/ketotarian nutrition program with ketone salts and esters
  • Saunas, cold plunge, and behavioral coaching
• Goal: build habits, establish belief, and create a daily routine that becomes a lifestyle
• Dr. Dale Bredesen serves as monthly consulting advisor for retreat cases

34:32 – Sponsor: Nature’s Marvels Bioregulatory Peptides

• Dr. Barrett has taken daily for 3+ years — “integral part of my wellness journey”
• Designed to optimize and restore the body’s natural processes
• Described as “the real deal for human optimization and longevity”

38:08 – Lifestyle as the Foundation

• Alzheimer’s requires a whole-team strategy: sleep, exercise, nutrition, stress management
• Behavior science concept of “activation energy” — it takes energy to change a habit
• Retreat provides dedicated Balinese staff known for warmth and professionalism
• Methylation adaptation lifestyle (per Dr. Kara Fitzgerald): reduces biological aging by 3.2 years in 8 weeks — study highlighted as must-see

41:01 – Root Causes: The “Poisoned” Food Supply

• Dr. Barrett on Ancel Keys and the demonization of saturated fat — fraudulent research funded by the sugar industry
• Seed oils, environmental toxins, and ultra-processed food as systemic threats
• “Health genocide” of Western societies driven by profit capture
• Dr. Jenkins references “The Corporation” (Canadian documentary) on institutional greed

44:02 – Protecting Yourself From Toxins

• Sulforaphane protective against benzene and other environmental toxins
• Cells have 30–40% reserve capacity — able to rejuvenate when properly supported (per Russian researcher Prof. Khavinson)
• Sauna (4–5x/week) dramatically reduces toxin burden
• “When you are healthy, you have 1,000 dreams. When you are unhealthy, you have one.”

46:42 – Clotho FDA Trials: Status Update

• Clotho Neuroscience company pursuing FDA trials for Alzheimer’s, Parkinson’s, and ALS
• Approval announced; trial design not yet publicly detailed; enrollment phase TBD
• Early results anticipated within 12–16 months
• First Parkinson’s patient referred by Dr. Jenkins: rapid-onset tremor following third COVID-19 vaccine; now enrolled in Clotho trial

49:03 – How to Connect with Dr. Dave Jenkins

• Website: youngerbyscience.com
• Free 15-minute introductory consultation available (while capacity allows)
• Documented scientific research on Clotho, hyperbaric oxygen, and lifestyle protocols
• Dr. Jenkins screens prospective patients and occasionally refers those who are not yet ready for behavioral change

Special Offer: Save 15% Using Code “SBPOD” At Checkout

Special Offer: Save 15% Using Code “SBPOD” At Checkout